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Summary
MASH1 and MASH2, mammalian homologues of the
Drosophila neural determination genes achaete-scute,
are members of the basic helix-loop-helix (bHLH) family
of transcription factors. We show here that murine P19
embryonal carcinoma cells can be used as a model
system to study the regulation and function of these
genes. MASH1 and MASH2 display complementary
patterns of expression during the retinoic-acid-induced
neuronai differentiation of P19 cells. MASH1 mRNA is
undetectable in undifferentiated P19 cells but is induced
to high levels by retinoic acid coincident with neuronai
differentiation. In contrast, MASH2 mRNA is expressed
in undifferentiated P19 cells and is repressed by retinoic
acid treatment. These complementary expression pat-
terns suggest distinct functions for MASH1 and MASH2
in development, despite their sequence homology. In
retinoic-acid-treated P19 cells, MASH1 protein ex-
pression precedes and then overlaps expression of
neuronai markers. However, MASH1 is expressed by a
smaller proportion of cells than expresses such markers.
MASH1 immunoreactivity is not detected in differen-
tiated cells displaying a neuronai morphology, sugges-
ting that its expression is transient. These features of
MASH1 expression are similar to those observed in vivo,
and suggest that P19 cells represent a good model system
in which to study the regulation of this gene. Forced
expression of MASH1 was achieved in undifferentiated
P19 cells by transfection of a cDNA expression con-
struct. The transfected cells expressing exogenous
MASH1 protein contained E-box-binding activity that
could be supershifted by an anti-MASHl antibody, but
exhibited no detectable phenotypic changes. Thus,
unlike myogenic bHLH genes, such as MyoD, which are
sufficient to induce muscle differentiation, expression of
MASH1 appears insufficient to promote neurogenesis.
Key words: induction, repression, achaete-scute, MASH,
neuronai differentiation, P19, embryonal carcinoma cells,
basic helix-loop-helix.
Introduction
Helix-loop-helix proteins constitute a recently ident-
ified family of transcription factors which appear to be
involved in the control of proliferation and cell type
determination. This family includes the myc genes
(Liischer and Eisenman, 1990), the ubiquitously ex-
pressed E12/E47 gene (also known as E2A) (Murre et
al., 1989a), myogenic determination genes such as
MyoD (Weintraub et al., 1991), and the Drosophila
neurogenic determination genes of the achaete-scute
complex (Villares and Cabrera, 1987). These proteins
share a basic region involved in DNA-binding, and an
adjacent helix-loop-helix domain required for homo-
and heterodimerization (Davis et al., 1990). Together
these domains constitute the basic helix-loop-helix
(bHLH) motif conserved among members of this family
(Murre et al., 1989b). Certain bHLH proteins display a
striking parallel conservation of amino acid sequence
and cell type specificity of expression. For example, the
Drosophila and C. elegans homologues of MyoD are
>85% identical to their mammalian counterparts (in
the bHLH region), and are specifically expressed in
myogenic precursor cells in their respective organisms
(Krause et al., 1990; Michelson et al., 1990).
MASH1 and MASH2 appear to be mammalian
homologues of the Drosophila achaete-scute genes,
showing >80% homology across the bHLH region but
diverging considerably from all other bHLH genes
(Johnson et al., 1990). The achaete-scute genes are
required for the development of subsets of neurons in
both the peripheral and the central nervous system of
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Drosophila (for review, see Ghysen and Dambly-
Chaudiere, 1988). In addition, the achaete-scute genes
are transiently expressed in neuronal precursors prior
to the expression of the mature neuronal phenotype
(Cabrera et al., 1987; Cubas et al., 1991; Romani et al.,
1989). An extensive analysis of MASHl protein
expression during rat embryonic development has
indicated that this gene is specifically expressed by
subsets of cells in both the peripheral and the central
nervous system (Lo et al., 1991). Moreover, MASHl
expression is transient; the protein appears before overt
neuronal differentiation and disappears as neuronal-
specific differentiation markers, such as SCG10 and
neurofilament, are expressed. The neuronal specific
and transient nature of MASHl expression during rat
embryonic development is similar, in its basic features,
to that of achaete-scute in Drosophila (Cabrera et al.,
1987; Cubas et al., 1991; Romani et al., 1989). Thus, as
in the case of MyoD, the neurogenic bHLH genes
appear to exhibit a parallel conservation of sequence
and cell type specificity.
Given the complex and dynamic pattern of ex-
pression of MASHl in vivo, studies of the regulation
and function of this gene would be facilitated by a
model cell culture system in which it was appropriately
regulated. Previously, we showed that MASHl and
MASH2 are specifically expressed in PC12 cells and
MAH cells, two neuronal precursor cell lines derived
from the peripheral sympathetic nervous system (John-
son et al., 1990). However, expression in these lines is
constitutive and only modestly regulated during neur-
onal differentiation. Here we have studied the ex-
pression of MASHl and MASH2 in P19 murine
embryonal carcinoma cells. P19 cells develop into
neurons and glia when aggregated and treated with
retinoic acid (Jones-Villeneuve et al., 1982; Jones-
Villeneuve et al., 1983; McBurney et al., 1988). We
have found that the expression of MASHl, but not
MASH2, is positively correlated with neural induction
in these cells. MASHl protein is transiently expressed
in the nuclei of a subset of cells that express neuronal
differentiation markers. The overall features of
MASHl expression in P19 cells are similar to those
observed in vivo (Lo et al., 1991). Forced expression of
MASHl from a transfected cDNA is insufficient to
bypass the requirement for retinoic acid. Thus,
although MASHl may be necessary for neuronal
differentiation, it is not sufficient.
Materials and methods
P19 cell culture and retinoic acid treatment
The P19 embryonal carcinoma cells were grown in DMEM
supplemented with 7.5% calf serum and 2.5% fetal bovine
serum and maintained as described elsewhere (Rudnicki et
al., 1988). To aggregate the cells, 5-10x 105 cells were cultured
in 10 cm Petri-grade dishes (Falcon). Retinoic acid (Sigma)
was added to a concentration of 1 fjM for 48 hours. The
aggregates were refed every 48 hours with medium lacking the
retinoic acid. For the experiment shown in Figs 5 and 6, the
aggregates were plated onto tissue culture-grade chamber
slides (Lab Tek, Inc.) 4 days after the initial aggregation and
retinoic acid treatment.
RNA isolation and RNase protections
Cytoplasmic RNA was isolated by phenol-chloroform extrac-
tion of postnuclear supernatants as described (Anderson et
al., 1974). MASHl and MASH2 mRNAs were analyzed by
solution hybridization and RNase protection essentially as
described (Melton et al., 1984). The antisense MASHl probe
was generated by T7 RNA polymerase transcription of a
PvwII digested MASHl cDNA. The antisense MASH2 probe
was generated by Sp6 RNA polymerase transcription of a
plasmid containing a 250 bp A7ioI-//i>zdIII fragment of the
MASH2 cDNA. The antisense y-actin probe was generated
by Sp6 polymerase transcription of a Fnu4H digested y-actin
plasmid (Enoch et al., 1986; Gunning et al., 1983). RNA
samples (5 n%) were hybridized with an excess of the 32P-
labeled RNA probes in 80% formamide, 40 raM PIPES pH
6.5, 10 mM EDTA, 400 mM NaCl for >12 hours at 50°C.
Hybrids were treated with 300 u/ml RNaseTl (BRL) and 10
ng/ml RNase A (Boehringer Mannheim) for 20 minutes at
42°C, followed by a 30 minutes incubation at 37°C with 1
^g/ml proteinase K, 0.5% SDS. Protected bands were
analyzed by electrophoresis on a 6% polyacrylamide/7 M
urea gel. Densitometry was performed using a Pharmacia
LKB Ultrascan XL laser densitometer.
Immunefluorescence staining
Monoclonal 5A5 producing hybridoma cells (Dodd et al.,
1988), and the monoclonal SSEA-1 hybridoma supernatant
(Solter and Knowles, 1978) were obtained from the Develop-
mental Studies Hybridoma Bank [NICHD (NO1-HD-6-
2915)]. 5A5 hybridoma supernatant was used undiluted.
SSEA-1 supernatant was used at a 1:3 dilution. Monoclonal
antibody HNK-1 (hybridoma cells obtained from ATCC) was
used as an ascites fluid diluted 1:250. In general, 5A5, HNK-1
and SSEA-1 labeling of surface antigens was performed on
live cells for 30 minutes followed by incubation with FTTC-
goat anti-mouse IgM (TAGO) and postfixation in 3.7%
formaldehyde for 10 minutes at room temperature. For flow
cytometry, the retinoic acid treated aggregates were stained in
suspension then dispersed by trituration in PBS containing 1
mM EDTA before postfixing in 1% formaldehyde for 10
minutes at room temperature and storing at 4°C until analyzed
on a cell sorter (Ortho). For double staining experiments, the
postfixed cells were permeabilized with 0.1% NP-40 and
incubated with anti-MASHIA hybridoma supernatant (1:1
dilution) overnight at 4°C (Lo et al., 1991). Secondary
antibody was either rhodamine- or phycoerythrin-goat anti-
mouse IgG (Southern Biotechnology Associates, Inc.). For
staining with anti-MASHIA alone, cells were fixed in 3.7%
formaldehyde 10 minutes at room temperature, permeabil-
ized with 0.1% NP-40, and incubated with the hybridoma
supernatent overnight at 4°C. Staining was visualized using an
avidin-biotin-HRP system (Vectastain ABC kit, Vector Labs,
Burlingame, CA) according to the manufacturer's instruc-
tions.
For separation of 5A5-positive and negative P19 popu-
lations for RNA analysis, activated magnetic beads (Dynal)
were coated with a goat anti-mouse IgM as described by the
manufacturer. These beads were then conjugated to the 5A5
antibody, reacted with dispersed retinoic-acid-treated P19
aggregates, and the 5A5-positive cells separated from the
5A5-negative cells using a magnet. Cytoplasmic RNA was
prepared from the two fractions.
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Preparation of nuclear extract and gel shift assays
P19 cells were aggregated for 4 days in the presence of 1 ^ M
retinoic acid then plated onto tissue-culture-grade substratum
for 1 day before harvest. Nuclear extracts were prepared as
described by Schreiber et al. (Schreiber et al., 1989). Gel shift
assays were performed as described (Benezra et al., 1990),
except that the high ionic strength buffer used for electrophor-
esis was as described by Murre et al. (Murre et al., 1991). The
oligonucleotides used contain the IgH-enhancer-like se-
quence in the wild-type muscle creatine kinase enhancer (top
strand: GATCCCCCCAACACCTGCTGCCTGA) or this
sequence mutated within the E-box concensus (top strand:
GATCCCCCCAACACGGTAACCCTGA) (Jaynes et al.,
1988; Lassar et al., 1989). Nuclear extract (7.5 //g) was
incubated with 0.5 ml ascites at 37°C for 20 minutes, then
mixed with 0.75 ng of double-stranded oligonucleotide probe
(20,000 cpm/ng). For competition experiments, 50 ng of
unlabeled wild-type or mutant oligonucleotide was also
added.
Plasmids and transfection
To construct the MASH1 expression vector pRSVMIE, a
Sacl-Sall fragment from the MASH1 cDNA Njl-13 was
cloned into pRSVSV40, an expression construct containing
the Rous sarcoma virus LTR, a polylinker, and SV40
sequences containing the small t intron and poly(A) addition
signal (J. Montgomery, unpublished). The Sad site in the
MASH1 cDNA is located between the first 2 methionines
which are 6 amino acids apart. Thus, the protein expressed
from this vector lacks the first 6 amino acids. This truncated
protein has equivalent DNA binding and transcriptional
activation activity in comparison to the full length protein
(Johnson et al., in preparation). pRSVMIE was co-trans-
fected with pUCneo (SV40 early promoter driving the
neomycin resistance gene) into P19 cells using the calcium-
phosphate DNA precipitation protocol (Wigler et al., 1979).
Cultures of 106 cells were exposed to 20 ng plasmid DNA for
16-20 hours then split into three 10 cm dishes. Stable
transformants were selected in 500 ^g/ml G418 the following
day. Colonies were pooled after 8-10 days of selection,
cultures expanded and then analyzed for expression of
MASH1, 5A5, HNK-1 and SSEA-1 by immunocytochem-
istry.
Results
Complementary regulation of MASH1 and MASH2
by retinoic acid
P19 cells undergo neuronal differentiation following
aggregation and treatment with retinoic acid (Jones-
Villeneuve et al., 1982; Jones-Villeneuve et al., 1983).
To determine whether the regulation of MASH1
and/or MASH2 mRNAs was correlated with neuronal
differentiation, we analyzed the timecourse of their
expression following a two-day exposure of aggregated
cells to 1 JIM retinoic acid. Under these conditions,
MASH1 and MASH2 mRNAs display complementary
patterns of expression (Fig. 1). MASH1 mRNA is not
detectable in undifferentiated P19 cells, but is detected
at low levels by 12 hours; expression then increases
through day 6 despite the withdrawal of retinoic acid on
day 2 (Fig. 1A and Fig. 2A). The levels of MASH1
expression attained were similar to those observed in
MAH cells, a peripheral sympathetic precursor cell line
(Birren and Anderson, 1990) in which MASH1 is
expressed (Johnson et al., 1990) (Fig. 1A, MAH). In
contrast, MASH2 mRNA is expressed in undifferen-
tiated P19 cells but declines to undetectable levels by
day 2 (Fig. IB and Fig. 2A). Densitometric analysis
indicates that the maximal abundance of MASH1
mRNA is 50-fold greater than MASH2 mRNA in
undifferentiated cells (Fig. 2A). Aggregation of P19
cells without addition of retinoic acid, which induces
differentiation of a small percentage of cells to an
embryonic endodermal phenotype (Jones-Villeneuve et
al., 1982), had no effect on the levels of MASH1 or
MASH2 mRNAs (Fig. 1, Agg Only). These data
therefore suggest that reciprocal changes in the ex-
pression of MASH1 and MASH2 mRNAs occur
specifically upon retinoic-acid-induced differentiation
of P19 cells.
The extent of MASH1 mRNA induction correlates
with the proportion of cells expressing neuronal
markers
To define further the relationship of MASH1 and
MASH2 expression to neuronal differentiation in the
P19 cultures, the appearance of two neuronal markers
was monitored following retinoic acid treatment using
the monoclonal antibodies HNK-1 (Abo and Balch,
1981) and 5A5 (Dodd et al., 1988). 5A5 recognizes the
highly polysialylated form of NCAM, an early and
specific pan-neuronal marker in vivo (Dodd et al.,
1988). HNK-1 recognizes a carbohydrate epitope but
has been shown to be neuron-specific in retinoic-acid-
treated P19 cultures (McBumey et al., 1988). Fluor-
escence microscopy of differentiating P19 cultures (see
below) indicates that these markers are expressed not
only by neurons, but also by morphologically undiffer-
entiated cells which may be neuronal precursors.
The percentage of HNK-1 and 5A5-positive cells in
the population was analyzed by flow cytometry in
parallel with analysis of the MASH1 and MASH2
mRNAs following retinoic acid treatment. Significant
numbers of 5A5-positive and HNK-1-positive cells are
observed on day 4 but not on day 2, during which
interval MASH1 mRNA accumulates to high levels and
MASH2 mRNA is no longer detectable (Fig. 2,
compare A and B). The percentage of cells expressing
the two neuronal markers, like the levels of MASH1
mRNA, reaches maximal levels by day 6. At this time
HNK-1 and 5A5-positive cells constitute 65% of the
total population (Fig. 2B; Fig. 3). As the percentage of
HNK-1 and 5A5-positive cells declines following day 6,
(perhaps reflecting an overgrowth of non-neuronal cells
in the culture), MASH1 mRNA levels fall and MASH2
mRNA increases. Lower doses of retinoic acid, which
yield lower percentages of 5A5-positive cells in the P19
cultures (Edwards et al., 1983), also yielded lower
amounts of MASH1 mRNA (data not shown). In
cultures aggregated in the absence of retinoic acid,
which resulted in no change in MASH1 and MASH2
mRNA expression (Fig. 1 AGG only), no 5A5
immunoreactivity was detected (Fig. 3B). These data
thus indicate a strong correlation between the percent-
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age of cells expressing neuronal markers and the extent
of MASH1 mRNA induction. MASH2 mRNA, by
contrast, is inversely correlated with the size of the
neuronal population and with the expression of
MASH1 mRNA.
MASH1 immunoreactivity overlaps the expression of
neuronal markers
The foregoing data indicated a parallel rise in MASH1
mRNA levels and the expression of neuronal markers
in differentiating P19 cells. However, these measure-
ments failed to reveal the precise relationship between
the expression of MASH1 and neuronal markers at the
cellular level. To address this issue, we used double-
label imunofluorescence to simultaneously detect
MASH1 and 5A5 or HNK-1. MASH1 immunoreac-
tivity was not detected in undifferentiated P19 cells.
The earliest detectable expression of MASH1 immuno-
reactivity following retinoic acid treatment was ob-
served at day 3 and was clearly localized to the nucleus
Fig. 1. RNase protection
analysis of MASH1 and
MASH2 mRNAs in a
timecourse of retinoic-acid-
treated P19 aggregates.
Cytoplasmic RNA was
analyzed from P19 aggregates
cultured with (RA + AGG) or
without (AGG only) retinoic
acid from 12 hours to 12 days.
Undiff: untreated P19
monolayers. MAH is a
neuronal precursor cell line
(Birren and Anderson, 1990)
and serves as a positive
control. The arrow indicates
the time when retinoic acid
was removed from the
cultures. (A) MASH1-
protected mRNA transcripts.
(B) MASH2-protected RNA
transcripts. The actin band
controls for the amount of
RNA in each lane. Panel (B)
is a longer exposure than panel
(A).
(Fig. AC). Aggregates containing MASHl-positive
nuclei at day 3 were not detectably labeled by 5A5 (Fig.
4B). By day 4, however, such MASHl-positive aggre-
gates were clearly labeled by 5A5 (Fig. 4, E and F).
These data show that the appearance of MASH1
immunoreactivity precedes that of the neuronal marker
5A5, and that 5A5 labeling appears in aggregates
containing MASHl-positive cells. However, although
regions of the aggregates containing MASHl-positive
and 5A5-positive cells clearly overlap, it was not
possible to determine at this level of resolution whether
individual cells co-express both markers.
To determine whether any MASHl-positive cells co-
express 5A5, two different methods were used. In the
first, 5A5-positive cells were isolated using antibody-
coated magnetic beads (see Materials and Methods)
and analyzed for MASH1 expression by RNase protec-
tion. MASH1 mRNA was clearly detected in the 5A5-
positive cell population (Fig. 5A). In the second
method, the co-expression of MASH1 and 5A5 in single
cells was detected by two-color immunofluorescence
MASH expression during P19 neuronal differentiation 79
r 8 0
DAY
Fig. 2. Correlation of MASH mRNA expression with
neuronal induction of P19 cells. (A) Densitometry was
performed and averaged from two independent RNase
protection experiments, one of them shown in Fig. 1. The
intensity of each MASHl or MASH2 protected band was
normalized to the respective y-actin band. The relative
levels of MASHl to MASH2 were estimated using y-actin
as an internal standard and assuming similar specific
activities of the MASHl and MASH2 probes. (B) The
percentage of 5A5- and HNK-1-positive cells was
determined by fluorescence activated cell sorting of
retinoic-acid-treated P19 cultures prepared in parallel with
the RNase protection experiments in (A). The data for
HNK-1 represent the average of two experiments and the
error bars represent the range.
(Fig. 5B). To quantify these data, aggregates were
dissociated and double-labeled for MASHl and 5A5 in
a single-cell suspension. This experiment confirmed
that up to 67% of MASHl-positive cells are co-labeled
by 5A5 at day 6 (n=611 cells counted). Thus, both
methods indicate that MASHl and 5A5 can be
expressed in the same cells. However, both methods
also indicate that MASHl is expressed by 5A5-negative
cells as well (Fig. 5A and data not shown). All MASHl-
positive nuclei appear to be present in 5A5-positive
aggregates (Fig. 4), indicating that MASHl-positive,
5A5-negative cells are intermingled with MASHl-
positive, 5A5-positive cells. Given that MASHl protein
precedes 5A5 on day 3, a likely explanation for these
observations is that the MASHl-positive, 5A5-negative
cells are precursors of MASHl-positive, 5A5-positive
cells, although this is presently difficult to prove.
In our retinoic-acid-treated P19 cultures, up to 65%
of the cells express 5A5 at day 6, as determined by flow
cytometry (Fig. 3A). Efforts to determine the pro-
portion of MASHl-positive cells by FACS were
unsuccessful due to the nuclear localization of the
antigen. As an alternative approach to this question,
dissociated cell suspensions of retinoic-acid-treated
aggregates were immunolabeled for MASHl using a
sensitive avidin-biotin peroxidase method (see Ma-
terials and Methods), and the proportion of positive
cells determined by manual counting. This analysis
indicated that MASHl-positive cells constitute approxi-
mately 3-5% of the P19 population at day 3, when
immunoreactivity is first detected (two independent
experiments; n=5,611 cells counted). The proportion
of MASHl-positive cells remains roughly constant
between days 3 and 6 (data not shown), while the
expression of MASHl mRNA increases continuously
over this interval (Fig. 2). Although differences in the
methods used to analyze 5A5 and MASHl expression
make difficult an accurate quantitative comparison of
these two antigens, the data strongly suggest that
MASHl is expressed by a smaller proportion of cells
than expresses 5A5.
The preceding analysis does not distinguish whether
5A5-positive cells expressing MASHl are differen-
tiated neurons or neuronal precursors. In order to
examine the expression of MASHl in cells displaying a
fully differentiated neuronal morphology, aggregated
and retinoic-acid-treated P19 cells were plated onto a
tissue culture substratum at day 4. Two days later,
neurons at the edges of the aggregates had extended
processes over a halo of flat cells which had migrated
onto the substratum. These cultures were examined by
double-label immunofluorescence for MASHl and
5A5. MASHl immunoreactivity was not detected in
process-bearing 5A5 neurons (Fig. 6, D-F). However,
MASHl immunoreactivity co-localizes to aggregates
containing 5A5-positive cells and not to the 5A5-
negative flat cells (Fig. 6, A-C). These data show that
MASHl immunoreactivity is associated with 5A5-
positive cell clusters which may contain immature
neurons or neuronal precursors, but is not detected in
fully differentiated neurons. This implies that the
expression of MASHl is transient in P19 cultures
undergoing neuronal differentiation.
Additional HLH proteins are induced by retinoic acid
in P19 cells
The low percentage of P19 cells expressing MASHl
after retinoic acid treatment could reflect a transient
expression of this gene by all cells or by a subset of cells.
In the latter case, MASHl might be only one of several
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Fig. 3. Histogram illustrating
distribution of 5A5 labeling in
P19 cells aggregated for 6 days
and exposed to retinoic acid
on days 1 and 2. Ordinate, cell
number; abscissa, fluorescence
intensity (log scale). (A)
Differentiating cells labeled
with monoclonal antibody 5A5
and fluorescein-conjugated
secondary antibody; (C)
control in which the primary
antibody was omitted. Note
the difference in fluorescence
distribution. Note also the
absence of any labeling in cells
aggregated without retinoic
acid treatment (compare B,
labeled with 5A5 and D,
lacking primary antibody). The
area bracketed by "2" was
used to calculate the
percentage of positive cells.
different bHLH proteins expressed by differentiating
P19 cells. To investigate this possibility, we assayed
nuclear extracts from P19 cells by an electrophoretic
mobility shift assay (EMSA) using an oligonucleotide
containing an IgH enhancer-like element ("E-box")
from the muscle creatine kinase gene (Jaynes et al.,
1988; Lassar et al., 1989). The detection of factors able
to bind specifically to this oligonucleotide would suggest
the presence of one or more proteins in the bHLH class
(Murre et al., 1989a).
Nuclear extracts prepared from undifferentiated P19
cells did not contain measureable levels of E-box-
binding activity (Fig. 7, lanes 1-7), suggesting either
that MASH2 protein is not functional or is expressed
below the detection limit of this assay. However,
extracts prepared from retinoic-acid-treated cultures
contained a protein or proteins that produced a strong
signal in the EMSA assay (Fig. 7, lane 8, lower arrow).
This binding activity was competed by an excess of
unlabeled oligonucleotide (Fig. 7, lane 14), but not by
an excess of an oligonucleotide containing mutations
that disrupt the concensus E-box and abolish binding of
MASH-E12 heterodimers (Fig. 7, lane 13) (Johnson et
al., submitted). To determine what fraction of the E-
box-binding activity is contributed by MASH1, we
performed a "super-shift" experiment by adding mono-
clonal anti-MASHl antibodies to the EMSA reaction.
Two of three independent anti-MASHl monoclonal
antibodies caused the appearance of a new band of
higher molecular weight (Fig. 7, lanes 10 and 11, upper
arrow). This band was not observed with a control
antibody of the same subtype (Fig. 7, lane 9), indicating
that it is specific for MASH1. Anti-MASHIC did not
cause a super shifted band, and may recognize an
epitope that is blocked by oligomerization and/or DNA
binding (T. S., unpublished observations). The inten-
sity of the super-shifted band could be increased by
supplementing the extracts with in vitro translated
MASH1 and E12 (not shown), demonstrating that
antibody was present in excess. The small proportion of
E-box-binding activity supershifted by the antibody
therefore suggests that MASH1 constitutes only a
fraction of the total bHLH proteins induced by retinoic
acid in P19 cells. These other, putative bHLH proteins
may constitute a single, highly abundant species or a
diversity of lower abundance species.
Constitutive expression of MASH1 in undifferentiated
P19 cells yields functional protein but is not sufficient
to induce neuronal differentiation
Expression of MyoD, a muscle-specific relative of
MASH1, is sufficient to cause myogenic differentiation
in a number of cultured mammalian cell types (Davis et
al., 1987; Weintraub et al., 1989). Since MASH1
expression is correlated with neuronal differentiation in
P19 cells and precedes that of other neuronal differen-
tiation markers, we wished to determine whether
expression of MASH1 was similarly sufficient to
promote neuronal determination. P19 cells were co-
transfected with pRSVMIE, a MASH1 cDNA under
the control of the Rous sarcoma virus LTR, and a
plasmid containing the neomycin resistance gene.
Preliminary experiments using transient transfection
failed to reveal evidence for phenotypic changes
induced by overexpression of MASH1. Stably trans-
formed G418-resistant cells were therefore generated,
and first examined for expression of MASH1 by
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Fig. 5. MASHl-positive cells co-express 5A5. (A) MASHl
RNase protection analysis of day 4 retinoic-acid-treated
P19 aggregates (total), the 5A5-positive fraction (5A5+),
and 5A5-negative fraction (5A5-). Cells were separated as
described in Materials and Methods. The y-actin serves as
a control for the amount of RNA assayed. Approximately
equal amounts of RNA were analyzed in each lane, but
much less RNA was recovered from the 5A5+ than the
5A5- fraction, as expected from the low proportion of
5A5+ cells at this stage (see Fig. 2B). (B) Co-expression
of MASHl and the neuronal marker 5A5 in the same cell.
Plated retinoic-acid-treated P19 aggregates were assayed on
day 6 for MASHl and 5A5 by two-color
immunofluorescence. False-color superimposed FITC and
rhodamine images were obtained using VidIM software
developed by S. Fraser, J. Stolber and G. Belford
(unpublished). The picture was taken with an SIT camera
on a Zeiss Universal epifluorescence microscope. The
nuclear staining for MASHl (red) is surrounded by cell-
surface labeling for 5A5 (green) in a single, well-isolated
cell.
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Fig. 7. Induction of E-box binding activity in retinoic-acid-
treated P19 cells. Extracts of untreated (control) P19 cells
(1-7) or retinoic-acid (RA)-treated P19 cells (8-14) were
used in an electrophoretic mobility shift assay to test
binding to an oligonucleotide containing the E-box (see
Materials and Methods). Added to the extracts were no
antibody (1,8), control antibody of the same subtype as the
test antibodies (2,9), anti-MASHIA (3,10), anti-MASHIB
(4,11), anti-MASHlC (5,12), unlabeled mutant
oligonucleotide (6,13) or unlabeled wild-type
oligonucleotide (7,14). Arrow indicates the gel shifted
band. The arrow* indicates the antibody dependent,
"supershifted" band. The complex formed in the control
extracts must be non-specific since both mutant and wild-
type oligonucleotides compete for the binding (6,7).
immunocytochemistry. We found that MASH1 was
expressed in only a small percentage of these pooled
transformants, even though they were maintained in
selection medium (Fig. 8A). These limitations prec-
luded an analysis of the effects of forced MASH1
expression in mass cultures. Therefore, the effect of
constitutive expression of MASH1 was examined using
a single-cell assay.
Stably transfected cells were doubly-labeled with the
anti-MASHIA antibody, and either the neuronal
markers 5A5 or HNK-1, or a marker for the undifferen-
tiated P19 cell, SSEA-1 (McBumey et al., 1988; Solter
and Knowles, 1978). This analysis indicated that
individual MASHl-positive P19 cells expressed neither
5A5 nor HNK-1, nor changed their morphology, in the
absence of retinoic acid (Fig. 8, B and C). Moreover,
many MASHl-positive cells continued to express
SSEA-1 (Fig. 8D). Thus, constitutive expression of
MASH1 appears insufficient to promote neuronal
differentiation in P19 cells.
To determine whether the MASH1 protein expressed
from the transfected cDNA was functional in undiffer-
entiated P19 cells, we examined the activity of trans-
fected MASH1 in nuclear extracts from clones of stably
transformed cells using a gel-shift DNA-binding assay
as described earlier (Fig. 7). From two clones contain-
ing the highest proportion of MASHl-immunoreactive
cells (up to 30%), a shifted complex was obtained using
an E-box-containing oligonucleotide (Fig. 9, lanes 13
and 14). The mobility of this complex was similar to that
observed for in vitro-translated MASH1 and E12 (Fig.
9, lane 16, lower arrow). Such shifts were not observed
using wild-type undifferentiated P19 cells (Fig. 9, lane 1
and Fig. 7, lanes 1-7). The mobility of the shifted
species was specifically retarded by incubation with
anti-MASHl monoclonal antibody (Fig. 9, lanes 9 and
12) but not by a control antibody (Fig. 9, lanes 8 and 11)
or by incubation without antibody (Fig. 9, lanes 7 and
10) (although such control incubations reduced the
intensity of the lower band, perhaps due to proteolytic
degradation). The antibody super-shifted species was
similar in size to that obtained using in vitro-translated
MASH1 plus E12 (Fig. 9, lane 16, upper arrow), or
extracts of wild-type retinoic-acid-treated P19 cells
(Fig. 9, lane 6); it was not detected in undifferentiated
cells (Fig. 9, lane 3). Since MASH1 homo-oligomers
are unable to bind the E-box probe used in this study
except at very high concentrations (Johnson et al.,
submitted), these data suggest that the exogenous
MASH1 expressed in stably transformed, undifferen-
tiated P19 cells is able to complex with E12 or an E12-
like protein to form functional DNA-binding com-
plexes. Moreover, the amounts of this activity are
similar to those observed in wild-type P19 cells exposed
to retinoic acid. Nevertheless, no differences in neural
marker expression, nor in the rate or extent of the
response to retinoic acid, were detected in these
transformed cells (L. Lo, unpublished data).
Discussion
The amino acid sequence of MASH1 is more than 80%
identical, in the bHLH domain, to that of the four
achaete-scute complex genes of Drosophila (Campu-
zano et al., 1985; Gonzalez et al., 1989; Villares and
Cabrera, 1987), and is more closely related to these
neurogenic determination genes than to other, mam-
malian members of the bHLH family (Johnson et al.,
1990). A detailed immunocytochemical analysis of
MASH1 expression during rat embryogenesis has
revealed that this protein is transiently expressed by
spatially restricted subsets of neural precursor cells (Lo
et al., 1991), consistent with the hypothesis that
MASH1 is a vertebrate neuronal determination gene.
These observations raise the related questions of how
MASH1 functions during neurogenesis, and what
factors regulate its complex and dynamic pattern of
expression.
As a first step towards addressing these questions, we
have identified a cell culture system in which MASH1
expression is induced concomitant with neuronal differ-
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Fig. 9. Stably transfected MASHl is able to bind an MCK E-box-containing oligonucleotide in nuclear extracts of
undifferentiated P19 cells. An antibody supershift experiment was performed as in Fig. 7. Two independent MASH1-
expressing clones ("clone 1" and "clone 2") contain an E-box-binding activity that is supershifted by the anti-MASHIA
monoclonal antibody (lanes 9 and 12; indicated by upper arrow). The supershifted band co-migrates with the band
obtained by supershifting in vitro-translated MASHl + E12 (lane 16), or nuclear extracts from wild-type retinoic-acid-
treated P19 cells (lane 6). In extracts incubated without antibody (lanes 7 and 10) or with control antibody (lanes 8 and
11), a weaker, faster-migrating band is seen (indicated by triangles); this band co-migrates with in vitro-translated MASHl
+ E12 incubated in the absence of antibody (lane 15; indicated by lower arrow). If the shift assay is performed without
any antibody incubation (see Materials and Methods), the amount of the MASHl-shifted band in the two clones is
increased (lanes 13 and 14; compare with lanes 7 and 10), perhaps indicating that proteolytic degradation occurs during the
antibody incubation. The intensity of the shifted band reflects the relative proportion of MASHl expression in the two
clones, as determined by immunocytochemistry (data not shown). Note that no shifted species are obtained with extracts
from non-transfected P19 cells grown without retinoic acid (lanes 1-3; see also Fig. 7).
entiation, the P19 embryonal carcinoma cells. Our
previous studies (Johnson et al., 1990) indicated that
MASHl is constitutively expressed in two cell lines
derived from the peripheral sympathoadrenal lineage
(Patterson, 1990): PC12 cells (Greene and Tischler,
1976) and MAH cells (Birren and Anderson, 1990).
Although these cell lines can be triggered to extend
neurites in response to specific growth factors such as
FGF and NGF, only a modest up-regulation of MASHl
expression is detected under these conditions. By
contrast, MASHl mRNA and protein are undetectable
in undifferentiated P19 cells but are induced upon
retinoic acid treatment. This difference may reflect the
likelihood that MAH and PC12 cells are already
determined for a neurogenic fate, whereas in the
developmentally earlier P19 line such a determination
event has not yet occurred. Thus, P19 cells constitute
the only model system so far identified in which the
regulation and function of MASHl can be studied
during early events in neurogenesis.
The features of MASHl regulation in P19 cells are
similar to those observed in vivo
Our recent studies of MASHl expression in vivo (Lo et
al., 1991) have revealed four basic features of regu-
lation of this gene which appear to be preserved by P19
cells. First, MASHl expression is restricted to the
embryonic nervous system; expression in non-neuronal
tissues so far has not been detected. In P19 cells,
MASHl is induced in parallel with neuronal differen-
tiation by retinoic acid, and immunoreactivity is
observed in the nuclei of cells expressing neuronal cell
surface markers. These data suggest that in P19 cells, as
in vivo, the induction of MASHl is specifically
associated with neurogenesis. Second, as in vivo,
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MASHl induction in P19 cells precedes the earliest-
detectable expression of neuronal terminal differen-
tiation markers: we observed MASHl immunoreac-
tivity prior to HNK-1 or 5A5 expression. Third, in vivo,
MASHl expression is extinguished concomitant with
overt neuronal differentiation; similarly, process-bear-
ing 5A5-positive neurons in P19 cultures were in-
variably MASHl-negative. Fourth, MASHl expression
in the embryonic nervous system is restricted to
spatially segregated domains of neuroepithelium. Our
observations suggest that MASHl expression may be
similarly restricted to a subset of neurogenic P19 cells
(but see below). Taken together, these data suggest that
in P19 cells, the expression of MASHl displays many of
the same characteristics as observed in vivo. This
system may therefore permit a detailed analysis of the
factors and mechanisms that regulate MASHl ex-
pression during neurogenesis.
Fate of MASH] -expressing P19 cells
MASHl protein appears in the nuclei of retinoic-acid-
treated P19 cells one day prior to the appearance of 5A5
immunoreactivity. Subsequently, many MASH1-
expressing cells co-express 5A5. At later times, 5A5-
positive neurons are invariably MASHl-negative.
These data suggest the progression MASHl",
5A5--+MASH1+, 5A5"^MASH1+, 5 A 5 + ^
MASHl", 5A5+ during the neuronal differentiation of
P19 cells. Unfortunately, the fact that MASHl is a
nuclear protein presently precludes the isolation of
living MASHl+ cells to directly determine their fate(s).
The number of MASHl+ cells appears small relative to
the number of 5A5+ cells over the course of differen-
tiation. This difference could reflect different sensi-
tivities or selectivities of the methods used to measure
MASHl and 5A5 expression. However the antibody
supershift data (Fig. 7) indicate that MASHl represents
a small fraction of the total E-box-binding activity
induced by retinoic acid. Taken together these data are
consistent with the idea that MASHl is expressed by a
subset of differentiating P19 cells. This could reflect a
situation in which all 5A5+ cells derive from MASHl+
precursors, but expression of MASHl is highly tran-
sient and asynchronous in the cell population. Alterna-
tively, only some 5A5+ neurons may derive from
MASHl+ precursors. There is evidence for phenotypic
heterogeneity in the P19 neuronal population (M.
McBurney, personal communication), heterogeneity
that is not revealed by pan-neuronal markers such as
5A5. Moreover, MASHl is expressed by subsets of
neural precursors in vivo. We therefore currently favor
the idea that MASHl is transiently expressed, by a
subset of neuronal precursors in P19 cells. Further
studies with more specific markers will be necessary to
clarify this issue, however.
Role of retinoic acid in the induction of MASHl
MASHl is induced in P19 cells by a two day exposure to
retinoic acid, but peak mRNA levels are not attained
until day 6. The slow kinetics of MASHl mRNA
accumulation may reflect a long half-life of the
message, asynchrony in the cell population, or the
involvement of secondary events in an induction
cascade rather than a direct action of the retinoic acid
receptor on the MASHl promoter. A number of
growth factors or putative growth factors, such as TGF/3
(Mummery et ah, 1990), int-1 (Schuuring et al., 1989;
St.-Arnaud et al., 1989) and interferon (D. Skup,
personal communication) are induced to maximal levels
within 48 hours of exposure of P19 cells to retinoic acid.
It is possible that the primary effect of retinoic acid may
be to induce the expression of such extracellular factors
which by signalling through appropriate receptors may
then induce MASHl. Such a mechanism would be
consistent with the requirement for aggregation, in
addition to retinoic acid treatment, to achieve efficient
induction of both MASHl expression and neuronal
differentiation. The availability of blocking antibodies
to various growth factors induced by retinoic acid in P19
cells may permit an assessment of their involvement in
MASHl induction.
The induction of MASHl by retinoic acid is also of
interest in light of the observation that the earliest
expression of MASHl in vivo is detected in cells lying
immediately adjacent to the floorplate in the ventral
spinal cord (Lo et al., 1991). Transplantation and
extirpation experiments have revealed that the floor-
plate exerts an inductive influence on the pattern of
cellular differentiation in the ventral spinal cord
(Yamada et al., 1991). One candidate for a floorplate-
derived inducing signal is retinoic acid (Wagner et al.,
1990). The induction of MASHl by retinoic acid in P19
cells is consistent with the idea that MASHl expression
in the ventral spinal cord is controlled by floorplate-
derived retinoic acid. This hypothesis should be testable
by examining MASHl immunoreactivity following in
vivo transplantation experiments or in vitro tissue
recombination experiments.
Reciprocal regulation of MASHl and MASH2
An unexpected result of these studies was that the
expression of MASHl and MASH2 mRNAs is recipro-
cally regulated during neuronal differentiation of P19
cells. In Drosophila, the four homologous transcription
units of the achaete-scute complex are all involved in
neuronal determination. Given the >90% sequence
identity between the two MASH genes in the bHLH
region, and the neuronal-specific expression of MASHl
in vivo, we expected to find the expression of both
MASHl and MASH2 correlated with neuronal differ-
entiation in P19 cells. Indeed, we previously observed
that both MASH genes are expressed, albeit at vastly
different levels, in MAH cells and PC12 cells, but not in
non-neuronal cells (Johnson et al., 1990; K. Zimmer-
man, unpublished data). The present data are the first
indication that MASHl and MASH2 may be expressed
in different cell types, and suggest that these two genes
may play different roles during development. In
support of this idea, in situ hybridization data indicate
that high levels of MASH2 mRNA are expressed in the
ectoplacental cone, an extra-embryonic structure
(unpublished observations). Furthermore, preliminary
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gene mapping data indicate that, in contrast to their
Drosophila counterparts, MASHl and MASH2 are
located on different chromosomes in the mouse (N.
Jenkins and U. Francke, personal communications).
The failure to conserve a linked arrangement of MASH
genes in evolution may be related to the failure to
conserve their tissue-specificity and, presumably, their
function.
MASHl is not sufficient to promote neuronal
differentiation of P19 cells
In an initial attempt to examine the function of MASHl
in P19 cells, we have achieved forced expression of this
gene in the undifferentiated cells by stable transform-
ation with a MASHl cDNA under the control of a
strong constitutive promoter. In the case of MyoD, a
muscle-specific relative of MASHl, forced expression is
sufficient to activate the endogenous myogenic program
in a number of different cell types (Davis et al., 1987;
Weintraub et al., 1989). Forced expression of MASHl,
however, appears insufficient to induce neurogenesis.
Nevertheless P19 cells are in principle competent to
undergo such differentiation, as shown by the effect of
retinoic acid.
These -negative results must be interpreted with
caution as the exogenous MASHl protein may not be
biologically active. However, gel shift experiments
using extracts from the stably transfected cells indicate
that the exogenous MASHl protein is able to bind to
DNA (Fig. 9). In addition, in a separate series of
experiments we have shown that transfected MASHl is
able to activate transcription from an exogenous muscle
creatine kinase enhancer in both 10 Tl/2 cells and P19
cells (Johnson et al., submitted). These data imply that
at least some of the transfected MASHl protein is
biologically active, supporting the conclusion that
MASHl alone is insufficient to induce neurogenesis in
P19 cells. In this respect, MASHl is not analogous in
function to MyoD, despite its structural similarity. We
cannot rule out the possibility that MASHl would be
sufficient for neurogenesis in a different cell context.
However, transfection of MASHl expression con-
structs into a number of different cell lines has failed to
reveal any detectable phenotypic changes (K. Z. and J.
E. J., unpublished data).
A reasonable explanation for our results is that
MASHl may act in combination with other factors in
P19 cells, and therefore be necessary but not sufficient
for neuronal determination. Our observations suggest
that a critical test of this hypothesis may be difficult. As
MASHl may be expressed in a small subset of
differentiating P19 cells, elimination of its function (by
antisense or other methods) would be expected to
produce a barely detectable decrease in the proportion
of cells expressing pan-neuronal markers such as 5A5.
(We have not identified other neuronal markers that
uniquely co-locahzed with MASHl in P19 cells.)
However the implication that differentiating P19 cells
may express other E-box-binding protein(s) besides
MASHl suggests that perturbations that interfere with
the activity of bHLH proteins as a family (Benezra, et
al., 1990) may prove successful in this system. Studies
such as these should provide a useful complement to
experiments aimed at interfering with MASHl function
during embryogenesis in vivo.
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